Detailed price information for Shionogi & CO Ltd (SGIOF) from The Globe and Mail including charting and trades.

Apnimed Inc. filed for a US initial public offering, as its oral drug to treat obstructive sleep apnea moves closer to being commercialized.

The health ministry on Nov. 22 sanctioned the use of an anti-COVID-19 drug manufactured by a domestic maker for the first ...

Detailed price information for Shionogi & CO Ltd (SGIOF) from The Globe and Mail including charting and trades.

Japanese drugmaker company Shionogi & Co. will invest $2.1 billion to raise its stake in ViiV Healthcare to 21.7%, reinforcing its focus on HIV and other major infectious diseases.

Shionogi & Co., Ltd. reported earnings for the nine months ended December 31, 2025, with sales rising to ¥360,684 million and net income reaching ¥158,225 million, both higher than the same period a ...

Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter, “Shionogi”) today announced its continued partnership with the ALS/MND Natural History ...

Shionogi (4507) has delivered a 13.3% change over the past year, with a 52-week range between 2,392.5 and 3,758.0. What Is the Average Daily Trading Volume of Shionogi (4507)? The average daily ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Shionogi (TSE:4507) has just ...